IIn a new long-term study, nintedanib (Ofev) improved forced vital capacity (FVC) and other idiopathic pulmonary fibrosis (IPF) symptoms. The findings were presented recently at the American Thoracic Society (ATS) 2015 International Conference in Denver.
Idiopathic Pulmonary Fibrosis (IPF) patients have many unmet healthcare needs and support solutions need to be implemented, according to a study published in the May, 2015 issue of the Journal of Advanced Nursing.
In a large, mutli-center study, researchers discovered potential biomarkers for accurately assessing idiopathic pulmonary fibrosis (IPF) disease progression.
The study, published in the March 11 issue of The Lancet Respiratory Medicine, was led by R. Gisli Jenkins, PhD, with the Division of Respiratory Medicine at the University of Nottingham in the United Kingdom. The PROFILE study was funded by GlaxoSmithKline R & D and the Medical Research Council.
Double-lung transplantation in patients with idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) was associated with better graft survival and patient survival than single-lung transplantation, according to a JAMA study.
Because there was no approved medication treatment for idiopathic pulmonary fibrosis (IPF) until mid-October, 2014, physicians primarily focused on non-pharmacological treatments to help patients improve. Even with FDA’s approval of nintedanib (Ofev) and pirfenidone (Esbriet), physicians will continue to recommend certain therapies that generally ease symptoms and improve patients’ quality of life.
While physicians laud FDA’s approval of nintedanib (Ofev) and pirfenidone (Esbriet) for treating idiopathic pulmonary fibrosis (IPF)—the first approved medications to treat the disease in the United Sates—they don’t know how to use them.
FDA approved two new therapies for idiopathic pulmonary fibrosis (IPF): pirfenidone (Esbriet, Roche) and nintedanib (Ofev, Boehringer Ingelheim). Both drugs are orally administered and will help slow the progression of IPF.
One of the most challenging aspects for physicians in diagnosing idiopathic pulmonary fibrosis (IPF) is the multitude of diseases that IPF can present as. Even after a battery of pathological tests and patient consultations, there are number of differential diagnoses relating to IPF.
Action Points: Two novel agents have been identified which have positive clinical effects in patients with idiopathic pulmonary fibrosis. It is unclear however how these agents will actually be used in practice.